These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 8233173

  • 1. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
    Florkowski CM, Brownlie BE, Elliot JR, Ayling EM, Turner JG.
    N Z Med J; 1993 Oct 27; 106(966):443-4. PubMed ID: 8233173
    [Abstract] [Full Text] [Related]

  • 2. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Reverter JL, Holgado S, Alonso N, Salinas I, Granada ML, Sanmartí A.
    Endocr Relat Cancer; 2005 Dec 27; 12(4):973-81. PubMed ID: 16322336
    [Abstract] [Full Text] [Related]

  • 3. Long-term thyroxine treatment and bone mineral density.
    Franklyn JA, Betteridge J, Daykin J, Holder R, Oates GD, Parle JV, Lilley J, Heath DA, Sheppard MC.
    Lancet; 1992 Jul 04; 340(8810):9-13. PubMed ID: 1351654
    [Abstract] [Full Text] [Related]

  • 4. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
    Sijanovic S, Karner I.
    Medscape Womens Health; 2001 Oct 04; 6(5):3. PubMed ID: 11698925
    [Abstract] [Full Text] [Related]

  • 5. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH, Chen JF, Yang BY, Liu RT, Tung SC, Chien WY, Lu YC, Kuo MC, Hsieh CJ, Wang PW.
    J Formos Med Assoc; 2004 Jun 04; 103(6):442-7. PubMed ID: 15278189
    [Abstract] [Full Text] [Related]

  • 6. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C, Golia F, Vignali E, Pinchera A.
    J Bone Miner Res; 1997 Jan 04; 12(1):72-7. PubMed ID: 9240728
    [Abstract] [Full Text] [Related]

  • 7. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
    Karner I, Hrgović Z, Sijanović S, Buković D, Klobucar A, Usadel KH, Fassbender WJ.
    Eur J Med Res; 2005 Nov 16; 10(11):480-8. PubMed ID: 16354602
    [Abstract] [Full Text] [Related]

  • 8. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
    De Mingo Dominguez ML, Guadalix Iglesias S, Martin-Arriscado Arroba C, López Alvarez B, Martínez Diaz-Guerra G, Martinez-Pueyo JI, Ferrero Herrero E, Hawkins Carranza F.
    Endocrine; 2018 Oct 16; 62(1):166-173. PubMed ID: 30014437
    [Abstract] [Full Text] [Related]

  • 9. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma.
    Görres G, Kaim A, Otte A, Götze M, Müller-Brand J.
    Eur J Nucl Med; 1996 Jun 16; 23(6):690-2. PubMed ID: 8662104
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
    Panico A, Lupoli GA, Fonderico F, Marciello F, Martinelli A, Assante R, Lupoli G.
    Thyroid; 2009 May 16; 19(5):437-42. PubMed ID: 19415993
    [Abstract] [Full Text] [Related]

  • 13. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B, Puavilai G, Rajatanavin R.
    J Med Assoc Thai; 1996 Sep 16; 79(9):563-7. PubMed ID: 8996984
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of Bone Mineral Density Using DXA and cQCT in Postmenopausal Patients Under Thyrotropin Suppressive Therapy.
    Kim K, Kim IJ, Pak K, Kim SJ, Shin S, Kim BH, Kim SS, Lee BJ, Jeon YK.
    J Clin Endocrinol Metab; 2018 Nov 01; 103(11):4232-4240. PubMed ID: 29982711
    [Abstract] [Full Text] [Related]

  • 16. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
    Baqi L, Payer J, Killinger Z, Hruzikova P, Cierny D, Susienkova K, Langer P.
    Endocr Regul; 2010 Apr 01; 44(2):57-63. PubMed ID: 20429634
    [Abstract] [Full Text] [Related]

  • 17. [Bone density in differentiated cancer of the thyroid gland treated by hormone-suppressive therapy. Study based on 51 cases].
    Eulry F, Bauduceau B, Lechevalier D, Magnin J, Crozes P, Flageat J, Gautier D.
    Rev Rhum Mal Osteoartic; 1992 Apr 01; 59(4):247-52. PubMed ID: 1496271
    [Abstract] [Full Text] [Related]

  • 18. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
    Sajjinanont T, Rajchadara S, Sriassawaamorn N, Panichkul S.
    J Med Assoc Thai; 2005 Nov 01; 88 Suppl 3():S71-6. PubMed ID: 16858944
    [Abstract] [Full Text] [Related]

  • 19. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
    Mazziotti G, Formenti AM, Frara S, Olivetti R, Banfi G, Memo M, Maroldi R, Giubbini R, Giustina A.
    J Clin Endocrinol Metab; 2018 Mar 01; 103(3):956-964. PubMed ID: 29121201
    [Abstract] [Full Text] [Related]

  • 20. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
    Diamond T, Nery L, Hales I.
    J Clin Endocrinol Metab; 1991 Jun 01; 72(6):1184-8. PubMed ID: 2026740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.